## WST: West Pharmaceutical Services, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.7% below STRENGTH zone (4.0-10.0%); PEG 3.38 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($252.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. West Pharmaceutical Services (WST): Reassessing Valuation After a 20% Share Price Decline**
- Source: Yahoo Finance Singapore | 20251217T051356 | Somewhat-Bullish | Relevance: 100%
- West Pharmaceutical Services (WST) has seen a 20% share price decline over the past year despite growing revenue and net income, prompting a reassessment of its valuation. While a narrative model suggests the stock is undervalued with a fair value of $346.07, its current P/E ratio of 39x is above the industry average, implying potential overvaluation. This creates a debate on whether the market is already pricing in future growth or if the stock presents an undervalued opportunity.

**2. West Pharmaceutical Services (WST): Reassessing Valuation After a 20% Share Price Decline**
- Source: Yahoo Finance | 20251217T050923 | Neutral | Relevance: 100%
- West Pharmaceutical Services (WST) has experienced a 20% share price decline over the past year despite growing revenue and net income, prompting a reassessment of its valuation. While a narrative model suggests the stock is 23% undervalued with a fair value of $346.07 due to strong earnings drivers and strategic growth, its current P/E ratio of 39x stands above industry averages. The article questions whether the market is already pricing in future growth or if current pricing indicates overvaluation compared to industry norms.

**3. Caxton Associates LLP Makes New $1.61 Million Investment in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251216T094137 | Bullish | Relevance: 100%
- Caxton Associates LLP has initiated a new position in West Pharmaceutical Services (NYSE:WST) with an investment of $1.61 million, acquiring 7,360 shares. This comes as institutional ownership in WST stands at 93.90%, with other major firms like Vanguard and State Street also increasing their stakes. Analysts maintain a "Moderate Buy" consensus rating for WST, with a target price of $342.20, following the company's strong Q3 earnings beat and positive FY2025 guidance.

**4. West Pharmaceutical Services Stock: Is WST Underperforming the Healthcare Sector?**
- Source: Yahoo Finance | 20251217T160913 | Somewhat-Bearish | Relevance: 99%
- West Pharmaceutical Services (WST) has underperformed the healthcare sector, with its stock down 23.6% from its 52-week high and lagging behind the Health Care Select Sector SPDR Fund (XLV) over various periods. Investor concerns about its outlook, operational headwinds, and pricing pressures have contributed to this decline, despite the company maintaining a "Strong Buy" consensus rating from analysts.

**5. New surgery guidelines expand use of vacuum dressings to protect incisions**
- Source: Stock Titan | 20251217T210944 | Somewhat-Bearish | Relevance: 65%
- Solventum announced new international consensus recommendations for the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings. Published in the International Wound Journal, these guidelines, based on a meta-analysis of 84 studies, expand ciNPT's use to high-risk patients and complex incisions, aiming to reduce surgical site complications. Solventum's Prevenaâ„¢ Therapy is highlighted as the only ciNPT system incorporating ROCF dressings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.38 signals overvaluation risk, limited margin of safety. Forward P/E 34.5x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.38 |
| Forward P/E | 34.5 |
| Current P/E | 37.8 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 4.7pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-0.63), momentum weakening. RSI neutral at 47. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.71% (CS: 34) | Neutral |
| RSI_14 | 47.3 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $268.64
- **Stop Loss:** $252.78 (5.9% risk)
- **Target:** $284.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 59
- **Position Value:** $15,849.76
- **Portfolio %:** 15.85%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*